LUPUS NEPHRITIS RESPONSE IN TERMS OF KIDNEY FUNCTION, URINE SEDIMENT AND SEROLOGICAL ACTIVITY AFTER SUBCUTANEOUS BELIMUMAB TREATMENT

被引：0
|
作者：
De la Rubia Navarro, M. [1 ]
Cortes, J. Ivorra [1 ]
Garcia, E. Grau [1 ]
Puig, L. Gonzalez [1 ]
Albuixech, R. Negueroles [1 ]
Cordellat, I. Martinez [1 ]
Ortiz-Sanjuan, F. [1 ]
Rodriguez, J. E. Oller [1 ]
Rodriguez, S. Leal [1 ]
Perales, C. Pavez [1 ]
Gil, J. J. Fragio [1 ]
Bernabeu, E. Vicens [1 ]
Barcena, C. Riesco [1 ]
Quispe, A. V. Huaylla [1 ]
Sanchez, L. Mas [1 ]
Munoz, P. [1 ]
Herranz, C. Najera [1 ]
Olmos, I. Canovas [1 ]
Ivorra, J. A. Roman [1 ]
机构：
[1] Hosp Univ La Fe, Reumatol, Valencia, Spain
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷
关键词：
D O I：
10.1136/annrheumdis-2022-eular.2944
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0435
引用
收藏
页码：1345 / 1346
页数：2
相关论文
共 50 条
  • [21] Urinary soluble VCAM-1 is a useful biomarker of disease activity and treatment response in lupus nephritis
    Andrese Aline Gasparin
    Nicole Pamplona Bueno de Andrade
    Vanessa Hax
    Penélope Esther Palominos
    Marina Siebert
    Romulo Marx
    Pedro Guilherme Schaefer
    Francisco Veríssimo Veronese
    Odirlei André Monticielo
    BMC Rheumatology, 4
  • [22] Urinary soluble VCAM-1 is a useful biomarker of disease activity and treatment response in lupus nephritis
    Gasparin, Andrese Aline
    Bueno de Andrade, Nicole Pamplona
    Hax, Vanessa
    Palominos, Penelope Esther
    Siebert, Marina
    Marx, Romulo
    Schaefer, Pedro Guilherme
    Veronese, Francisco Verissimo
    Monticielo, Odirlei Andre
    BMC RHEUMATOLOGY, 2020, 4 (01)
  • [23] Urinary λ Free Light Chain Concentration Is Associated with Disease Activity and Response to Treatment in Proliferative Lupus Nephritis
    Hanaoka, Masanori
    Gono, Takahisa
    Kawaguchi, Yasushi
    Kaneko, Hirotaka
    Koseki, Yumi
    Katsumata, Yasuhiro
    Takagi, Kae
    Ichida, Hisae
    Baba, Sayumi
    Okamoto, Yuko
    Ota, Yuko
    Kataoka, Sayuri
    Yamanaka, Hisashi
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S238 - S238
  • [24] URINARY SOLUBLE VCAM-1 IS A USEFUL BIOMARKER OF DISEASE ACTIVITY AND TREATMENT RESPONSE IN LUPUS NEPHRITIS
    Gasparin, A. A.
    Pamplona Bueno de Andrade, N.
    Hax, V.
    Palominos, P.
    Siebert, M.
    Marx, R.
    Shaefer, P.
    Verissimo Veronese, F.
    Monticielo, O.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1502 - 1503
  • [25] Urinary T Cells and Macrophages Strongly Reflect the Disease Activity, Kidney Function, and the Histopathologic Classification in Patients with Lupus Nephritis.
    Wada, Yoko
    Sakatsume, Minoru
    Nakano, Masaaki
    Narita, Ichiei
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S726 - S726
  • [26] SUCCESSFUL TREATMENT WITH BELIMUMAB AFTER INADEQUATE RESPONSE TO PREVIOUS THERAPEUTIC REGIMENS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. REAL LIFE EXPERIENCE
    Athanassiou, P.
    Tzanavari, A.
    Katsavouni, C.
    Banti, T.
    Kostoglou-Athanassiou, I.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : S82 - S82
  • [27] Predicting treatment response and clinicopathological findings in lupus nephritis with urine epidermal growth factor, monocyte chemoattractant protein-1 or their ratios
    Ngamjanyaporn, Pintip
    Worawichawong, Suchin
    Pisitkun, Prapaporn
    Khiewngam, Khantong
    Kantachuvesiri, Surasak
    Nongnuch, Arkom
    Assanatham, Montira
    Sathirapongsasuti, Nuankanya
    Kitiyakara, Chagriya
    PLOS ONE, 2022, 17 (03):
  • [28] Urine L-selectin reflects clinical and histological renal disease activity and treatment response in lupus nephritis across multi-ethnicity (vol 14, 1200167, 2023)
    Shen, Yiwei
    Vanarsa, Kamala
    Yin, Zhihua
    Zhang, Ting
    Castillo, Jessica
    Dai, Min
    Zou, Linghua
    Qin, Ling
    Wang, Jieying
    Guo, Qiang
    Saxena, Ramesh
    Petri, Michelle
    Shen, Nan
    Ye, Zhizhong
    Mohan, Chandra
    Ding, Huihua
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [29] INDIRECT COMPARATIVE CLINICAL EFFECTIVENESS OF INTRAVENOUS AND SUBCUTANEOUS FORMULATIONS OF BELIMUMAB FOR THE TREATMENT OF ADULT PATIENTS WITH ACTIVE, AUTOANTIBODY-POSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS WITH HIGH DISEASE ACTIVITY
    Parks, D.
    Ramachandran, S.
    Kurtinecz, M.
    Asukai, Y.
    Alfonso-Cristancho, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 857 - 858
  • [30] Interleukin-6 release from peripheral mononuclear cells is associated to disease activity and treatment response in patients with lupus nephritis
    Esposito, Pasquale
    Balletta, Mario M.
    Procino, Alfredo
    Postiglione, Loredana
    Memoli, Bruno
    LUPUS, 2009, 18 (14) : 1329 - 1330
12345